Iron Mountain Incorporated (NYSE: IRM) is trusted by more than 240,000 customers in 61 countries, including approximately 95% of the Fortune 1000, to help unlock value and intelligence from their assets through services that transcend the physical and digital worlds. Our broad range of solutions address their information management, digital transformation, information security, data center and asset lifecycle management needs. Our longstanding commitment to safety, security, sustainability and innovation in support of our customers underpins everything we do.

Iron Mountain Incorporated (Delaware)Common Stock REIT

Mirum Pharmaceuticals received a Buy rating and an $115.00 price target from J.P. Morgan analyst today. The word on The Street in general, suggests...

Mirum Pharmaceuticals (MIRM) Gets a Buy from J.P. Morgan

Mirum Pharmaceuticals ( ($MIRM) ) just unveiled an announcement. On May 15, 2026, Mirum Pharmaceuticals issued $690 million of 0.00% Convertible Se...

Mirum Pharmaceuticals Issues $690 Million Convertible Senior Notes

In a report released on May 14, Jonathan Atkin from RBC Capital maintained a Buy rating on Iron Mountain, with a price target of $147.00. The compa...

RBC Capital Keeps Their Buy Rating on Iron Mountain (IRM)

In a report released today, Mani Foroohar from Leerink Partners maintained a Buy rating on Mirum Pharmaceuticals, with a price target of $154.00. A...

Leerink Partners Remains a Buy on Mirum Pharmaceuticals (MIRM)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright assigned a Buy rating to Mirum Pharmaceuticals, with a price target of $185...

Mirum Pharmaceuticals (MIRM) Gets a Buy from H.C. Wainwright

Jefferies analyst reiterated a Buy rating on Iron Mountain today and set a price target of $148.00. The word on The Street in general, suggests a S...

Iron Mountain (IRM) Receives a Buy from Jefferies

In a report released today, Lisa Walter from RBC Capital maintained a Buy rating on Mirum Pharmaceuticals, with a price target of $142.00. Accordin...

RBC Capital Sticks to Its Buy Rating for Mirum Pharmaceuticals (MIRM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on InflaRx (IFRX) and Mirum Pharmaceuticals (MIRM) with...

Analysts Are Bullish on These Healthcare Stocks: InflaRx (IFRX), Mirum Pharmaceuticals (MIRM)

The latest announcement is out from Mirum Pharmaceuticals ( ($MIRM) ). On May 4, 2026, Mirum Pharmaceuticals reported that its VISTAS Phase 2b tria...

Mirum’s Volixibat Succeeds in Phase 2b PSC Itch Trial

Analysts have been eager to weigh in on the Real Estate sector with new ratings on Invitation Homes (INVH) and Iron Mountain (IRM). Invitation Home...

Analysts Offer Insights on Real Estate Companies: Invitation Homes (INVH) and Iron Mountain (IRM)

In a report released today, Tobey Sommer from Truist Financial maintained a Buy rating on Iron Mountain, with a price target of $140.00. According ...

Market Cap	$24.96B	P/E Ratio	23.75
52W High	$134.09	52W Low	$77.77
Div Yield	345.6%	Payout Ratio	360.6%
EPS Growth 3Y	-36.6%	52W Position	89.7%
Overall Score	58	Value Score	60
Quality Score	52	Technical Score	63

EPS Current Est	$5.4	EPS Next Est	$5.97
EPS Growth Est	+10.6%	DPS Growth 3Y	9.2%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IRM	$128.27	+1.43%	362.55K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IRM	$128.27	+1.4%	362.55K
3
4
5
6

IRM

IRM

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Iron Mountain Incorporated (Delaware)Common Stock REIT Data in Excel

Get Iron Mountain Incorporated (Delaware)Common Stock REIT Data in Excel